StockData
Nkarta, Inc. logo

Nkarta, Inc. (NKTX) company profile

NKTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 7/30
$1.25+0.04 (+3.31%)

Close on Nov 17, 2026Market cap $89.53MP/E –Yield 0.00%

About Nkarta

Pharmaceutical Preparations, SIC 2834

The company is a clinical-stage biopharmaceutical organization focused on creating allogeneic, off-the-shelf engineered natural killer cell therapies. Its primary pipeline candidate, NKX019, is an engineered chimeric antigen receptor natural killer cell product designed to target the CD19 antigen. This lead candidate aims to treat various autoimmune conditions, including lupus nephritis, primary membranous nephropathy, systemic sclerosis, idiopathic inflammatory myopathy, and antineutrophil cytoplasmic antibody-associated vasculitis. It previously evaluated product candidates in oncology indications before redirecting its primary resources toward autoimmune diseases.

The organization operates two current good manufacturing practice facilities situated in South San Francisco, California. These internal facilities supply cell therapy products for ongoing and future clinical trials, with capacity planned to support potential commercial production. Clinical evaluations and investigator-sponsored trials involving its therapies take place across collaborating medical centers and universities within the United States.

Summary of the business section of Nkarta's latest annual report, written by StockData.

Company profile

Company

Legal name
Nkarta, Inc.
Headquarters
South San Francisco, CA
Address
1150 Veterans Boulevard 94080
Phone
(925) 407-1049
Employees
108, Dec 31, 2025
Industry
Pharmaceutical Preparations
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
Ernst & Young LLP, California

Stock & identifiers

Ticker
NKTX
Exchange
Nasdaq
IPO date
Jul 13, 2020
Shares outstanding
72M, Aug 5, 2026
Public float
$82.60M, Jun 30, 2025
Filer category
Non-accelerated filer<br>Smaller reporting company
SEC CIK
1787400
CUSIP
65487U108
ISIN
US65487U1088
FIGI
BBG00JXHS9G7
Share class FIGI
BBG00JXHS9H6
EIN
47-4515206

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Paul J. HastingsChief Executive Officer, Director390,247
Nadir MahmoodPresident167,727
Shawn Marshall RoseSee Remarks70,000
Alicia J. HagerChief Legal Officer146,735
Ralph BrandenbergerChief Technical Officer124,796
Alyssa LevinSee Remarks102,662
David ShookSee Remarks190,955
Capital Healthcare Fund LP RADirector–
Zachary ScheinerDirector–
Leone D. PattersonDirector–
Angela ThedingaDirector–
George VratsanosDirector–
Michael DybbsDirector–
Rajeev M. ShahDirector7,805,129
Peter KolchinskyDirector–
RA Capital Nexus Fund, L.P.Director–
Ra Capital Management, L.P.Director10,050,818
Simeon GeorgeDirector3,333,333
Ali BehbahaniDirector–

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025$2.98M$2.04M$1.31M$28–
FY2024$3.99M$1.54M$2.62M$38–

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryStock awardsOption awardsIncentive payOtherTotalvs. prior year
Paul J. Hastings
Chief Executive Officer
$674.38K$236.25K$1.71M$344.95K$10.50K$2.98M-25%
Nadir Mahmood
President
$543.25K$155.00K$434.65K$252.61K$10.50K$1.40M-58%
Shawn Rose
Chief Medical Officer and Head of Research and Development
$316.59K–$709.30K$189.72K$9.16K$1.22M–

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Jul 13, 2020
Offer price
$18.00
Securities offered
14,000,000
Gross proceeds
$252.00M
Exchange
Nasdaq
First trading day
Jul 10, 2020
First-day close
$47.90+166.1%
Lock-up ends (est.)
Jan 6, 2021

“Our common stock has been approved for listing on the Nasdaq Global Select Market under the symbol “NKTX.” The initial public offering price is $18.00 per share.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of December 31, 2025, we had 108 full-time employees, 28 of whom have advanced degrees including but not limited to Ph.D., M.D.”

Corporate history

Events identified from SEC filings

See a number that looks wrong?